Related Experiment Video
Updated: Feb 28, 2026

qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue
Published on: July 9, 2014
Clinical Characteristics and Predictors of Antiviral Treatment Duration in Hospitalized Patients with Ulcerative
1Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Kocaeli University, 41001 İzmit, Turkey.
Abstract:
Cytomegalovirus (CMV) colitis is a significant entity in hospitalized patients with ulcerative colitis, particularly during immunosuppressive therapy. The factors associated with antiviral treatment duration remain incompletely defined. This retrospective cohort study included hospitalized adult patients with ulcerative colitis and immunohistochemically confirmed CMV colitis. Baseline demographic, clinical, endoscopic, and laboratory characteristics were evaluated for the cohort and stratified by antiviral treatment duration of ≤14 days and >14 days. Correlation analyses were performed between tissue CMV polymerase chain reaction (PCR) viral load and laboratory parameters. Receiver operating characteristic analysis identified a tissue CMV PCR cut-off associated with prolonged antiviral therapy. The study included 52 patients (median age, 41.5 years; 65.4% male). Fourteen patients received biologic therapy and were younger and had higher C-reactive protein levels than those who did not receive biologics. Tissue CMV PCR viral load was higher in patients who received antiviral therapy for >14 days. The analysis identified a tissue CMV PCR cut-off value of 162,000 IU/mg, with an area under the curve of 0.69, sensitivity of 70.4%, and specificity of 76.0%. Tissue CMV PCR viral load showed a weak negative correlation with serum albumin levels (Spearman 's r = -0.34, p < 0.05). Tissue CMV PCR viral load is associated with antiviral treatment duration and may help identify patients with ulcerative colitis-associated CMV colitis who require prolonged therapy.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

